DO-BO

How to decode Market Access in Canada: Are there essential tips for success, Tara Cowling and Jody Filkowski?

In the newest episode of MAP – the Market Access podcast, experts Tara Cowling and Jody Filkowski unpacks the complexities and nuances of Canada’s market access for pharmaceuticals and medical devices. From regulatory hurdles to intricate reimbursement pathways, they shed light on what it takes to successfully navigate this diverse and challenging landscape.

Whether you’re dealing with drugs or medical devices, understanding the distinct processes in Canada, including the differences between provinces and the role of private versus public payers, is crucial. This episode offers a deep dive into the practical strategies and real-world challenges faced by industry professionals working within the Canadian healthcare system. They also share insights about the emerging role of digital health in Canada, and the potential changes with the introduction of the Canadian Drug Agency.

Related

In this episode of the Market Access Podcast, Erica Bersin – founder of ERO Health Communications – joins Dr. Stefan Walter to discuss the changing role of patient involvement in healthcare. Drawing on her experience in both Europe and the U.S., Erica explains how single-payer systems make patient engagement easier, while the U.S. faces more […]

In this episode of the Market Access Podcast, Dr. Stefan Walzer sits down with strategy consultant and XR advocate Günther Illert to explore how virtual, augmented, and extended reality are reshaping healthcare—from patient training and pain therapy to surgical planning and medtech education. Learn how cross-sector collaboration and early adoption—especially outside traditional reimbursement systems—can unlock […]

Tune in to this new episode of MAP to explore New Zealand’s unique healthcare and reimbursement landscape with Dr. Stefan Walzer and health economist Dr. Julius Ohnberger. Learn how PHARMAC combines HTA and payer roles, why equity and Māori health outcomes are central to market access and what global pharma can gain from launching in […]